Dabigatran Versus Apixaban in Cerebral Venous Thrombosis

Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications

NCT Number	NCT06551415
Lead Sponsor	Kafrelsheikh University
Conditions	Cerebral Venous Sinus Thrombosis
Enrollment	200 participants
Start Date	2021-08-01
Primary Completion	2024-09-01 (estimated)
Study Completion	2024-10-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-13